FindTrial
Sign In

MGTA-145

BIOLOGICAL5 trials

Sponsors

Ensoma, Surbhi Sidana, MD

Conditions

Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaHealthyHealthy DonorsHealthy VolunteersMultiple MyelomaMyelodysplastic SyndromeRelated Donors Donating PBSC to a Family Member

Phase 1

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor
CompletedNCT03932864
EnsomaHealthy Volunteers
Start: 2019-04-22End: 2020-02-25Updated: 2024-01-11
Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
CompletedNCT04154670
EnsomaHealthy, Renal Insufficiency
Start: 2019-11-07End: 2020-03-24Updated: 2024-01-11

Phase 2

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
CompletedNCT04552743
Surbhi Sidana, MDMultiple Myeloma
Start: 2020-10-05End: 2022-06-30Updated: 2022-09-10
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
TerminatedNCT04762875
EnsomaAcute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Healthy Donors +2
Start: 2021-06-16End: 2022-03-14Updated: 2024-11-06
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
TerminatedNCT05445128
EnsomaSickle Cell Disease
Start: 2022-06-24End: 2023-02-02Updated: 2025-07-25

Related Papers

Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.
2024-10-093 citations
A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia
Blood2022-11-15
Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study
Blood2021-11-054 citations
Phase 2 study of MGTA-145 + plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.
Journal of Clinical Oncology2021-05-201 citations